Newleos Announces Dosing of First Participant in Phase 1b Study of NTX-2001 for Alcohol Use Disorder

Newleos doses the first participant in a Phase 1b study of NTX-2001, a potential first-in-class TAAR1 partial agonist for ...
Business Wire

Anova Announces First Patient Enrolled to Phase 1/2a Study of DB107 for the Treatment of High-Grade Gliomas

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two patients in the ...

CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

CREATE Medicines, Inc., ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today ...
Nasdaq

Fractyl Health Submits Clinical Trial Application for First-in-Human Study of RJVA-001 Gene Therapy for Type 2 Diabetes and Obesity

Fractyl Health announced a first-in-human trial for RJVA-001, targeting T2D and obesity, pending regulatory approval by 2026. Fractyl Health, Inc. has announced the submission of the first module of ...
ascopubs.org

A phase I dose-escalation study of a first-in-class HIF1 and HIF2 dual inhibitor R01 in patients with advanced tumors.

Targeting the PYGL with chicoric acid to normalize glucose metabolism to inhibit progress in NSCLC. INSIHGT revived: Unified 3D tissue profiling for spatially resolved, multi-marker, quantitative ...
FiercePharma

China approves 4 new drugs, including a global first-in-class medicine

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...
The Punch

Six double first-class law graduates share trials, triumphs

Discover the trials and triumphs of six female graduates who achieved a double first-class in law. Learn their study habits, ...
Las Vegas Sun

Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC1 Pipeline in Oncology

Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, is leading an oversubscribed $75 million (€ 65 million 2 ) Series C financing round in Adcendo ApS ...